Gastrointestinal Diseases  >>  midazolam hydrochloride  >>  Phase 1
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
midazolam hydrochloride / Generic mfg.
NCT00866853: TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.

Completed
1
16
Europe
TMC435
Tibotec Pharmaceuticals, Ireland
Hepatitis C, Viruses
07/09
07/09
NCT01060566: Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

Completed
1
24
US
VX-770
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
03/10
04/10
NCT01405612: Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy Volunteers

Completed
1
14
Europe
Midazolam, Ulimorelin, TZP101
Norgine
Digestive System Disorders
07/11
07/11
NCT01489943: A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

Completed
1
24
US
GSK1605786 500 mg, Midazolam 3 mg, Pioglitazone 15 mg, Omeprazole 40 mg, Rosuvastatin 10 mg
GlaxoSmithKline
Crohn's Disease
11/11
11/11
NCT00996879: Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects

Completed
1
48
US
Midazolam, BMS-791325
Bristol-Myers Squibb
Hepatitis C
09/13
09/13
NCT01525628: Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Completed
1
72
US, Canada, Europe
midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin
Boehringer Ingelheim
Hepatitis C, Chronic
12/13
10/14
NCT02045966: Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects

Completed
1
16
US
Cocktail, DCV 3DAA FDC, BMS-791325
Bristol-Myers Squibb
Hepatitis C
04/14
04/14

Download Options